
Abstract This study aims to explore healthcare professionals' perceptions of barriers and clinical impact influencing the adoption of non‐invasive imaging modalities for endometriosis diagnosis. A global cross‐sectional survey was distributed through formal and informal FIGO committee networks. Content analysis was used to analyze the qualitative responses from the survey. Of the 360 respondents, 83.3% were gynecologists. In total, seven main topics were identified as barriers, including the lack of training and expertise ( n = 173, 48.2%), cost and accessibility ( n = 98, 27.3%), professional and institutional challenges ( n = 28, 7.8%), diagnostic limitations ( n = 15, 4.2%), equipment quality ( n = 11, 3.1%), patient barriers ( n = 9, 2.5%), and cultural and clinical resistance ( n = 4, 1.1%). Respondents felt that adopting non‐invasive imaging techniques for endometriosis diagnosis could lead to general impact on clinical practice ( n = 118, 32.8%), changes in surgical and medical management ( n = 84, 23.3%), shift in diagnostic approach ( n = 77, 21.4%), challenges and considerations ( n = 32, 9.7%), and improved patient‐centered care ( n = 25, 6.9%). This study highlights barriers and potential clinical impact of integrating non‐invasive imaging into endometriosis diagnosis. Although clinicians recognize its potential to improve diagnostic accuracy and reduce reliance on surgery, widespread adoption is hindered by training gaps, resource limitations, and systemic variability.
Abstract Objective This study maps the evidence on fertility preservation, reproductive counseling, contraception, hormone replacement therapy (HRT) and care pathway integration for women with hereditary gynecological cancer predisposition, principally breast cancer genes 1 and 2 (BRCA1 and BRCA2) and Lynch syndrome, and derives a clinical decision‐making framework. Methods A scoping review was conducted following the Joanna Briggs Institute methodology and PRISMA extension for scoping reviews (PRISMA‐ScR). The core search covered seven databases, Google Scholar and 11 gray literature sources from January 2000 to June 2025; a targeted supplementary search of MEDLINE and Embase for contraception and HRT was run to 7 October 2026 in response to peer review. Records from both searches were combined for selection. Two reviewers screened records and charted data, and findings were synthesized narratively. Results Of 5113 records identified, 4273 were screened after de‐duplication, 280 were assessed in full, and 99 sources were included. Evidence came mainly from high‐income countries and concerned BRCA1/2 carriers; 12 sources focused on Lynch syndrome. Oocyte and embryo cryopreservation were feasible, but live‐birth outcomes were rarely reported. Oral contraception was associated with lower ovarian cancer risk and, in BRCA1 carriers, a modest increase in breast cancer risk with longer use. HRT after premenopausal risk‐reducing salpingo‐oophorectomy was not associated with increased breast cancer risk in women without breast cancer yet remained underused. Counseling content and timing were inconsistent, and evidence for Lynch syndrome, low‐ and middle‐income countries, and minority ethnic populations was sparse. Conclusion Reproductive counseling covering fertility preservation, preimplantation genetic testing, contraception, and HRT should begin at genetic diagnosis and precede irreversible surgery. The proposed 10‐step framework requires prospective evaluation.
Abstract Objective Cardiotocography (CTG) is the standard method for intrapartum fetal monitoring. Modern systems acquire fetal heart rate (FHR) using external Doppler ultrasound (US) or internal fetal scalp electrocardiography (ECG). We evaluated whether mode‐specific FHR signal dropout was associated with perinatal asphyxia and whether it should be retained as an informative, mode‐aware feature for downstream predictive models. Methods We conducted a retrospective multicenter cohort study using routinely collected clinical and CTG data from Mercy Hospital for Women, Melbourne, Australia, for 2010–2021; Werribee Mercy Hospital, Melbourne, Australia, for 2010–2021; and the Czech CTU‐UHB database from University Hospital Brno, for 2010–2012. A total of 46 662 labor episodes at ≥36 weeks' gestation with ≥15 min of interpretable CTG data in the final 60 min before birth were analyzed (32 242 in the model‐development cohort, 548 in the Czech validation cohort, and 13 872 in the Australian community validation cohort). The exposure was mode‐specific FHR dropout, classified as US low dropout, US high dropout (>30%), ECG low dropout, or ECG high dropout (>30%). The primary outcome was sustained perinatal asphyxia, defined using a Delphi‐consensus composite of clinical, biochemical, and neurologic criteria. Results In the model‐development cohort, 860 cases of perinatal asphyxia occurred (2.67%, 95% CI 2.49%–2.85%). Compared with US low dropout, ECG high dropout was associated with higher risk of asphyxia (inverse probability weighting IPW‐adjusted odds ratio [OR] 3.14, 95% CI 2.20–4.48; targeted maximum likelihood estimation‐adjusted OR 2.08, 95% CI 1.21–3.58), corresponding to an absolute risk increase of 2.27% (one additional case per 44 births). Survival analysis supported elevated hazards (HR 4.76, 95% CI 2.98–7.62). External validation supported the direction of association, although estimates varied across cohorts. Conclusion In retrospective multicenter analyses, high FHR dropout during ECG monitoring was associated with increased perinatal asphyxia risk. These findings support evaluating mode‐specific dropout as an informative signal‐quality feature in future predictive models. Prospective validation of such models is needed before clinical implementation.
Abstract Objective To estimate the incidence, diagnostic features, and perinatal outcomes of massive subchorionic thrombohematoma (MST) in Japan. Methods This nationwide multicenter retrospective study (2018–2023) analyzed confirmed cases of MST, defined as a laminated hematoma with a maximum thickness ≥1 cm. Maternal characteristics, sonographic patterns, and perinatal complications were evaluated. Results Of 346 741 deliveries across 87 tertiary perinatal centers, 69 pathologically confirmed MST cases were identified at 27 centers, yielding an incidence of 0.019% (69/346 741). Median maternal age was 33 years and body mass index (BMI) was 21.1. Chronic hypertension was present in 8.7% (6/69). Diagnoses occurred antenatally in 81.2% (56/69) and postpartum in 18.8% (13/69). Ultrasound findings included placentomegaly or a placental mass with variable echogenicity. During follow‐up, echogenicity changed in 28% of cases and lesion size in 57%. Perinatal outcomes included induced abortion in 13.0% (9/69), miscarriage before 22 weeks in 5.8% (4/69), stillbirth in 7.2% (5/69), preterm birth in 52.2% (36/69), and term delivery in 21.7% (15/69). Among preterm births, one neonatal death and two infant deaths occurred. After excluding induced abortion and miscarriage before 22 weeks, small‐for‐gestational‐age status was present in 53.6% (30/56) of infants, pre‐eclampsia occurred in 16.1% (9/56), and preterm premature rupture of membranes occurred in 23.2% (13/56). Neonatal intensive care unit admission was required for 82.4% (42/51) of live births. Conclusion MST is a rare but high‐risk placental disorder associated with miscarriage, stillbirth, preterm birth, impaired fetal growth, and pre‐eclampsia. When MST is suspected antenatally, close maternal and fetal surveillance is warranted.